RMD · News · 20260807N
Guidance / Outlook
RESMED INC · 2026-08-07 · Importance 62 · Surprise 68 · In source text
ResMed issued fiscal 2027 guidance for 5%-7% core revenue growth and non-GAAP diluted EPS of $12.00-$12.25. The outlook is below Wall Street revenue expectations and incorporates the $75 million impact from the Astral field safety action, which assumes no Astral ventilator sales during FY2027. Excluding the Astral impact and the MatrixCare and Noctrix portfolio changes, analysts cited underlying core EPS growth of approximately 12%-14%.
Key facts
- Guidance for FY2027 core revenue growth was stated as 5%-7% and non-GAAP EPS guidance of $12 to $12.25. source
- ResMed's shares fell about 6% after projecting fiscal 2027 revenue below Wall Street expectations. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | +3.0% | Guidance for FY2027 core revenue growth was stated as 5%-7% and non-GAAP EPS guidance of $12 to $12.25. |
| net_income | positive | probable | — | Guidance for FY2027 core revenue growth was stated as 5%-7% and non-GAAP EPS guidance of $12 to $12.25. |